Supplying millions of doses across therapeutic classes, we currently market anti-infectives and critical care products globally, with an active specialty pipeline in development.
The changing landscape of patient needs, and generic competition, offers opportunities for differentiated products which set us apart from the rest. We continue working towards expanding the reach of our existing products with innovative dosage and delivery platforms and through the addition of more specialty products to our portfolio. We believe agility is key, and our flexible business model reflects the same. We have a portfolio driven go-to-market strategy to achieve success across all markets.
Since its inception in 2020, Steriscience has completed 15+ ANDA filings, with 5+ products already launched in the US. We have also received approval on our first 505(b)(2) NDA that was co-developed in partnership with a US CRO – a key addition to our value added ready-to-use portfolio. We have 10+ products under approval with the FDA, including 3 from our value-added ready-to-use portfolio. We have 8+ launches planned in the coming year based on approvals.
Steriscience has launched 7 products in the US through strong regional partners, including penicillins and critical care products facing acute shortages, serving those in need navigating constraints through a resilient supply chain. With 5+ strong partnerships already in place, we are actively seeking to expand our global presence through new opportunities for our portfolio of differentiated injectables across the Unites States of America.
Over the last 30 months, Steriscience has developed 30+ products and completed 20+ global filings; with first set of approvals received across the key markets of Canada and Europe.
We have secured a pan portfolio partnership in Canada with two top players in the hospital segment across the anti-infective, critical care and the value-added portfolio and have 3+ launches planned in the coming year based on approvals.
To maximize the value of our portfolio including the specialty and ready-to-use programs, we are actively seeking to expand our global presence through new opportunities with strong regional players across North America, Europe, Latin America, APAC and MENA.
Our mission is to be a global injectables player providing patients access to critical hospital medications and improving patient care.
We are actively pursuing potential partners worldwide for: